Welcome to our dedicated page for Sage Therapeutic news (Ticker: SAGE), a resource for investors and traders seeking the latest updates and insights on Sage Therapeutic stock.
About Sage Therapeutics (NASDAQ: SAGE)
Sage Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming the treatment landscape for central nervous system (CNS) disorders. With a mission to improve the lives of patients suffering from life-threatening and rare CNS diseases, Sage Therapeutics focuses on discovering, developing, and delivering innovative medicines that address critical unmet medical needs. The company operates at the intersection of neuroscience and pharmacology, leveraging its expertise to advance a robust pipeline of therapies targeting CNS receptor systems, including GABA and NMDA.
Core Business Areas
Sage Therapeutics is primarily engaged in three key therapeutic areas:
- Depression: Developing groundbreaking treatments for major depressive disorder (MDD) and postpartum depression (PPD), including FDA-approved therapies like ZULRESSO and ZURZUVAE.
- Neurology: Addressing complex neurological conditions such as seizure disorders and cognitive impairments through innovative compounds.
- Neuropsychiatry: Advancing therapies for a range of psychiatric and cognitive disorders, with a focus on improving patient outcomes and quality of life.
Product Pipeline and Scientific Approach
Sage Therapeutics employs a science-driven approach to drug development, targeting CNS receptor systems that play a critical role in brain function. The company's proprietary chemistry platform has produced multiple compounds with preclinical and clinical activity, including:
- ZULRESSO (brexanolone): The first FDA-approved treatment for postpartum depression, administered as a CIV injection.
- ZURZUVAE (zuranolone): A novel oral medication for postpartum depression, reflecting Sage's commitment to patient-centric solutions.
- Investigational Therapies: SAGE-718 for cognitive disorders and SAGE-324 for essential tremor and other neurological conditions.
By targeting specific CNS pathways, Sage aims to address the underlying mechanisms of disease, offering patients therapies that are both effective and well-tolerated.
Industry Position and Competitive Landscape
Sage Therapeutics operates in the highly specialized and competitive biopharmaceutical sector, focusing on CNS disorders—a field with significant unmet medical needs. The company differentiates itself through its deep scientific expertise, robust clinical foundation, and strategic partnerships with leading academic institutions and industry players. Despite challenges such as regulatory approvals and competition from other CNS-focused companies, Sage's innovative pipeline and targeted approach position it as a key player in the neuroscience space.
Value Proposition
Sage Therapeutics delivers value by addressing critical gaps in CNS disorder treatments. Through its innovative therapies, the company aims to improve patient outcomes, reduce healthcare costs, and enhance quality of life for individuals affected by debilitating CNS conditions. Sage's commitment to rigorous science, clinical excellence, and patient-centric solutions underscores its role as a leader in advancing brain health medicines.
Conclusion
With a focus on neuroscience innovation, a robust pipeline of therapies, and a commitment to addressing unmet medical needs, Sage Therapeutics is at the forefront of transforming the treatment paradigm for CNS disorders. By leveraging its scientific expertise and strategic partnerships, the company continues to make significant strides in improving the lives of patients worldwide.
Sage Therapeutics (Nasdaq: SAGE) will host the first Sage Science Spotlight webcast on May 20, focusing on SAGE-718, its lead neuropsychiatry product candidate.
The webcast will cover advancements in treating cognitive disorders related to NMDA receptor dysfunction and discuss new data from the PARADIGM Study for patients with mild cognitive impairment due to Parkinson’s disease. Sage will also initiate a Phase 2 study in Huntington’s disease. Expert speakers will include Sage's Chief Research Officer and a leading neurologist.
Access the webcast on Sage's investor page.
Sage Therapeutics reported Q1 2021 results, showcasing advancements in its depression, neurology, and neuropsychiatry franchises. The company highlighted significant clinical data for zuranolone, SAGE-324, and SAGE-718, with ongoing Phase 3 trials anticipated to support potential approvals. Revenue from ZULRESSO reached $1.6 million, a decline from $2.3 million in Q1 2020. R&D expenses decreased to $58.1 million. Despite a net loss of $95.8 million, Sage expects a strong cash position of over $1.7 billion by year-end. The company continues to pursue innovative therapies for brain health disorders.
Sage Therapeutics, a biopharmaceutical company focused on treating brain disorders, will present at two investor conferences in May 2021. The first is the Bank of America Health Care Conference on May 11, 2021, at 10:15 am ET, followed by the RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 8:35 am ET. Live webcasts will be available on the company's investor page, with replays accessible for 30 days. Sage's mission is to develop therapies that improve brain health and transform treatment for depression and neurological disorders.
Sage Therapeutics, Inc. (Nasdaq: SAGE) will host a live webcast on May 4, 2021, at 8:00 a.m. ET to discuss its first quarter 2021 financial results and recent business updates. Investors can access the webcast via the company's investor page. A replay will be available about two hours post-event and archived for 30 days. Sage Therapeutics is dedicated to developing innovative therapies aimed at treating brain disorders, particularly focusing on depression, neurology, and neuropsychiatry.
Sage Therapeutics and Biogen announced positive topline results from the Phase 2 KINETIC Study of SAGE-324 for essential tremor treatment. The study achieved its primary endpoint with a significant reduction in upper limb tremor score, showing a 36% decrease in the SAGE-324 group versus 21% in placebo (P=0.049). Severe tremor patients demonstrated an even greater 41% reduction. Safety profiles were consistent with previous data, and plans for further development of SAGE-324 are underway, reflecting the substantial unmet medical need in treating essential tremor affecting over 6.4 million in the U.S.
Sage Therapeutics (NASDAQ: SAGE) announced its participation in the Stifel 3rd Annual CNS Day fireside chat on March 31, 2021, at 8:00 am ET. This event highlights Sage's commitment to developing innovative therapies for brain disorders. Investors can access a live webcast on the company's investor page, with a replay available two hours post-event and archived for 30 days. Sage Therapeutics focuses on transforming treatment approaches for depression, neurology, and neuropsychiatry, aiming to improve brain health and patient outcomes.
Sage Therapeutics reported 12-month data from the Phase 3 SHORELINE Study evaluating zuranolone for major depressive disorder (MDD). The 30 mg cohort demonstrated favorable safety, with 51% reporting at least one adverse event, consistent with previous studies. 73.5% of patients achieved a clinical response, requiring an average of 2.2 treatments within the year. Interim data from the 50 mg cohort showed 80.5% response rates. Sage aims to provide further data at upcoming conferences, while continuing to assess zuranolone’s long-term efficacy and safety.
Sage Therapeutics (NASDAQ: SAGE) announced the departure of Chief Operating Officer Mike Cloonan, effective May 3, 2021. Cloonan, who has been with the company for four years, expressed intentions to pursue a Chief Executive Officer role in the biopharmaceutical sector. CEO Barry Greene commended Cloonan for his contributions and confirmed that his responsibilities will be temporarily assumed by Greene as Sage continues its growth strategy. The company remains focused on advancing its multiple brain health programs and has no immediate plans to fill the COO position.
Sage Therapeutics reported strong financial results for Q4 and the full year 2020, driven by a collaboration with Biogen valued at $3.1 billion. In Q4, Sage posted a net income of $974.9 million, significantly up from a net loss of $168.7 million in 2019. Revenue reached $1.1 billion, primarily from the Biogen partnership. Sage's cash position improved to $2.1 billion, facilitating ongoing development efforts including 10 anticipated data readouts in 2021 across its brain health portfolio. The company is focused on advancing its pipeline for major depressive disorder and other neurological conditions.
Sage Therapeutics (NASDAQ: SAGE) will present at two upcoming investor conferences in February and March 2021. The conferences are the SVB Leerink Partners' 10th Annual Global Healthcare Conference on February 25 at 8:00 am ET and the Cowen & Co. 41st Annual Health Care Conference on March 1 at 4:00 pm ET. Investors can access live webcasts of the presentations on Sage's investor website, with replays available 30 days post-event. Sage is focused on creating innovative therapies for brain disorders, aiming to enhance treatment options and improve patient outcomes.
FAQ
What is the current stock price of Sage Therapeutic (SAGE)?
What is the market cap of Sage Therapeutic (SAGE)?
What does Sage Therapeutics specialize in?
What are Sage Therapeutics' key products?
How does Sage Therapeutics differentiate itself in the biopharmaceutical industry?
What therapeutic areas does Sage Therapeutics focus on?
What is Sage Therapeutics' approach to drug development?
What is the significance of targeting GABA and NMDA receptors?
Is Sage Therapeutics a publicly traded company?
What challenges does Sage Therapeutics face in its industry?
What is Sage Therapeutics' mission?
What role do strategic partnerships play for Sage Therapeutics?
